http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
수종의 내부연결형 임플란트에서 연결부의 형태에 따른 응력분포의 유한요소 분석
정병현,이경제,강동완 대한치과보철학회 2012 대한치과보철학회지 Vol.50 No.2
Purpose: This study was performed to compare the stress distribution pattern of abutment-fixture connection area using 3-dimensional finite element model analysis when 5 different implant systems which have internal connection. Materials and methods: For the analysis, a finite element model of implant was designed to locate at first molar area. Stress distribution was observed when vertical load of 200 N was applied at several points on the occlusal surfaces of the implants, including center, points 1.5 mm, 3.0 mm away from center and oblique load of 200 N was applied 30º inclined to the implant axis. The finite element model was analyzed by using of 3G. Author (PlassoTech, California, USA). Results: The DAS tech implant (internal step with no taper) showed more favorable stress distribution than other internally connected implants. AS compare to the situations when the loading was applied within the boundary of implants and an oblique loading was applied, it showed higher equivalent stress and equivalent elastic strain when the loading was applied beyond the boundary of implants. Regardless of loading condition, the abutments showed higher equivalent stress and equivalent elastic strain than the fixtures. Conclusion: When the occlusal contact is afforded, the distribution of stress varies depending on the design of connection area and the location of loading. More favorable stress distribution is expected when the contact load was applied within the diameter of fixtures and the DAS tech implant (internal step with no tapering) has more benefits than the other design of internally connected implants. 연구 목적: 본 연구는 3차원 유한요소분석을 통해 특징적인 내부연결구조를 갖는 5종의 임플란트의 고정체와 지대주의 연결방식에 따른 응력분산을 알아보고자 하였다. 연구 재료 및 방법: 본 실험을 위한 유한요소모델은 하악 제1대구치부에 임플란트가 식립되고 상부구조물로 3형 금합금을 사용하는 것으로 가정하였다. 응력분산은 200 N의 하중이 교합면의 중심, 중심에 1.5 mm 외측, 중심에서 3.0 mm 외측에 수직으로 가해지고 임플란트의 장축과 30º의 각도로 경사하중이 가해지도록 하여 분석하였다. 유한요소모델에 대한 해석작업은 3G.Author (PlassoTech, California, USA)를 사용하여 이뤄졌다. 결과: 경사가 없는 내부계단 구조를 가지는 DAS tech의 임플란트의 경우, 내부연결구조를 갖는 다른 임플란트에 더 유리한 응력분산을 보였다. 하중이 임플란트 고정체의 외형선 이내에 가해지는 경우와 비교하여 외형선 바깥이나 경사력으로 전해지는 경우 더 높은 응력을 보였으며 하중조건과 관계없이 임플란트 고정체보다는 지대주에 더 큰 응력이 집중되었다. 결론: 교합력이 가해졌을 때 응력분산은 임플란트의 연결부의 형태와 하중이 가해지는 위치에 따라 달라졌으며 내부계단 구조를 가지는 DAS tech의 임플란트를 사용한 경우와 고정체의 외형선 이내에 하중이 가해졌을 경우에 더 유리한 응력분산을 보였다.
Lee, Gyeong-Won,Park, Sung Woo,Go, Se-Il,Kim, Hoon-Gu,Kim, Min Kyoung,Min, Chang-Ki,Kwak, Jae-Yong,Bae, Sang-Byung,Yoon, Sung-Soo,Lee, Je-Jung,Kim, Ki Hwan,Nam, Seung-Hyun,Mun, Yeung-Chul,Kim, Hyo Jun S.Karger 2018 Acta haematologica Vol.140 No.3
<P><B><I>Background:</I></B> The neutrophil-to-lymphocyte ratio (NLR) is an independent prognostic marker in solid and hematological cancers. While the derived NLR (dNLR) was shown to be non-inferior to the NLR in large cohorts of patients with different cancer types, it has not been validated as a prognostic marker for multiple myeloma (MM) to date. <B><I>Methods:</I></B> Between May 22, 2011 and May 29, 2014, 176 patients with MM from 38 centers who were ineligible for autologous stem cell transplantation were analyzed. The dNLR was calculated using complete blood count differential data. The optimal dNLR cut-off value according to receiver operating characteristic analysis of overall survival (OS) was 1.51. All patients were treated with melphalan and prednisone combined with bortezomib. <B><I>Results:</I></B> The complete response rate was lower in the high dNLR group compared to the low dNLR group (7 vs. 26.1%, respectively; <I>p</I> = 0.0148); the corresponding 2-year OS rates were 72.2 and 84.7%, respectively (<I>p</I> = 0.0354). A high dNLR was an independent poor prognostic factor for OS (hazard ratio 2.217, 95% CI 1.015–4.842; <I>p</I> = 0.0458). <B><I>Conclusion:</I></B> The dNLR is a readily available and cheaply obtained parameter in clinical studies, and shows considerable potential as a new prognostic marker for transplantation-ineligible patients with MM.</P>
Lee, Je-Hwan,Kim, Yoo-Jin,Sohn, Sang Kyun,Yoon, Sung-Soo,Kim, Hawk,Cheong, June-Won,Lee, Won-Sik,Lee, Gyeong-Won,Lim, Sung-Nam,Kim, Min Kyoung,Lee, Ho Sup,Kim, Hyeoung-Joon Elsevier 2017 Leukemia research Vol.60 No.-
<P><B>Abstract</B></P> <P>We retrospectively analyzed the results of hypomethylating therapy in 586 patients (azacitidine in 423 and decitabine in 163) with International Prognostic Scoring System (IPSS) lower-risk myelodysplastic syndrome (MDS). The patients were reclassified with newer scoring systems (revised IPSS [R-IPSS], revised WHO classification-based Prognostic Scoring System [R-WPSS], and Lower Risk Prognostic Scoring System [LR-PSS]), and 21.8–38.4% of patients had high or very high risk features by the newer scoring systems. Median overall survival (OS) was 27.3 months and newer scoring systems well stratified the patients in terms of OS (R-IPSS, <I>P</I> =0.001; R-WPSS, <I>P<</I> 0.001; LR-PSS, <I>P<I> <</I> </I> 0.001). Hematologic improvement (HI) was observed in 279 patients (47.6%). OS differed by the achievement of HI (39.4% vs. 36.2%, <I>P</I> =0.067). The differences were significant only in patients of intermediate or high risk group by LR-PSS (<I>P</I> =0.034) or R-IPSS (<I>P</I> =0.018). In summary, IPSS lower-risk MDS included a broad range of prognosis, and hypomethylating therapy induced HI in approximately half of the patients. Achievement of HI was associated with longer survival, especially in patients with intermediate or high risk features by newer scoring systems. Hypomethylating therapy seems to have potential benefits in IPSS lower-risk MDS.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Some IPSS lower-risk patients had high risk features by newer scoring systems. </LI> <LI> IPSS lower-risk patients were well stratified by newer systems for survivals. </LI> <LI> Hematologic improvement was observed in 48% after hypomethylating therapy. </LI> <LI> Achievement of hematologic improvement was associated with longer survival. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Lee, Je-Hwan,Joo, Young-Don,Kim, Hawk,Bae, Sung Hwa,Kim, Min Kyoung,Zang, Dae Young,Lee, Jung-Lim,Lee, Gyeong Won,Lee, Jung-Hee,Park, Jae-Hoo,Kim, Dae-Young,Lee, Won-Sik,Ryoo, Hun Mo,Hyun, Myung Soo,K American Society of Hematology 2011 Blood Vol.118 No.14
<B>Abstract</B><P>We conducted a phase 3 randomized trial comparing 2 different doses of daunorubicin as induction chemotherapy in young adults (60 years of age or younger) with acute myeloid leukemia (AML). Of 383 patients who were analyzed, 189 received standard-dose daunorubicin (SD-DN, 45 mg/m2 per day times 3 days) and 194 received high-dose daunorubicin (HD-DN, 90 mg/m2 per day times 3 days) in addition to cytarabine (200 mg/m2 per day times 7 days) to induce complete remission (CR). The CR rates were 72.0% in the SD-DN arm and 82.5% in the HD-DN arm (P = .014). At a median follow-up of 52.6 months, overall (OS) and event-free (EFS) survival were higher in the HD-DN arm than in the SD-DN arm (OS, 46.8% vs 34.6%, P = .030; EFS, 40.8% vs 28.4%, P = .030). Differences in CR rate and both OS and EFS remained significant after adjusting for other variables (CR, hazard ratio [HR], 1.802, P = .024; OS, HR, 0.739, P = .032; EFS, HR, 0.774, P = .048). The survival benefits of HD-DN therapy were evident principally in patients with intermediate-risk cytogenetic features. The toxicity profiles were similar in the 2 arms. In conclusion, HD-DN improved both the CR rate and survival duration compared with SD-DN in young adults with AML. This study is registered at www.clinicaltrials.gov as #NCT00474006.</P>
천식과 호산구성 기관지염에서 CD4, CD8 림프구 침윤
이상엽 ( Lee Sang Yeob ),이승룡 ( Lee Seung Lyong ),김제형 ( Kim Je Hyeong ),신철 ( Sin Cheol ),심재정 ( Sim Jae Jeong ),강경호 ( Kang Gyeong Ho ),유세화 ( Yu Se Hwa ),인광호 ( In Gwang Ho ),이지혜 ( Lee Ji Hye ),정운용 ( Jeong U 대한결핵 및 호흡기학회 2003 Tuberculosis and Respiratory Diseases Vol.55 No.5
포터블 뇌파 바이오피드백 시스템을 위한 전치증폭기 및 DSP 하드웨어의 설계
이경일 ( Lee Gyeong Il ),안보섭 ( An Bo Seob ),박정제 ( Park Jeong Je ),이승하 ( Lee Seung Ha ),조진호 ( Jo Jin Ho ),김명남 ( Kim Myeong Nam ) 한국센서학회 2003 센서학회지 Vol.12 No.3
본 논문에서는 포터블 뇌파 바이오피드백시스템을 위한 전치증폭부 및 디지털 신호처리부의 하드웨어 구현에 대한 연구를 수행하였다. 뇌파의 특성을 고려하여 외부 잡음을 제거할 수 있는 뇌파 획득용 전치증폭부를 구현하였다. 측정된 뇌파에는 안전도, 근전도, 심전도 등의 신호들이 포함되어 있으며 이들은 뇌파 분석에 방해가 된다. 따라서 이러한 신호들을 제거하기 위하여 적응여파기 알고리듬을 수행하고 전치증폭부를 실시간으로 구동하는 디지털신호처리부를 구현하였다. 시뮬레이션 파형과 실제 뇌파를 적용한 실험결과를 통하여 개발된 시스템의 성능을 확인할 수 있었으며 휴대형 뇌파 바이오피드백 시스템에 적용 가능함을 확인하였다. In this study, we carried out a study for implementation of the pre-amplifier and the digital signal processing part for the potable EEG biofeedback system. As we consider characteristics of the EEG signal, we designed the pre-amplifier to obtain the EEG signal to be reduced noise signal. Because the EEG signal include EOG, EMG, ECG signals etc, it is difficult to analyze of the EEG signal. Therefore, we developed DSP board and operation program which was embed the LMS adaptive filter algorithm and operate with the pre-amplifier in the real time. The simulation signal and pure EEG signal is used in the experiment. As the result, we confirmed good efficiency of developed system and possibility of application to the portable EEG biofeedback system.